Codexis Enters Into Research Collaboration With Schering-Plough
Codexis, Inc. announced that it has signed a research agreement with Schering-Plough Corporation to develop a novel synthetic process for use by Schering-Plough. The collaboration will focus on improving biocatalyst productivity using Codexis' proprietary MolecularBreeding(TM) pharmaceutical process re-engineering platform. Codexis will receive research funding and milestone payments upon successful completion of certain objectives of the research. Further terms were not disclosed.
According to Codexis, the company's unique MolecularBreeding(TM) protein and strain engineering technology platform creates superior biological catalysts (biocatalysts) -- either enzymes or fermentation strains -- crafted specifically for cutting-edge chemical processes that can enable pharmaceutical process development, shorten process development timelines, dramatically improve existing manufacturing processes and increase chemical development productivity. Codexis estimates that its platform technology can reduce cost of goods by 35% - 65% and capital expenditures by over 35%. In addition, this platform technology can create new intellectual property opportunities, which can help extend the lifetime of drug products.
Other news from the department business & finance
